Waltham, MA, United States of America

Xiulong Shen

This inventor holds 1 USPTO granted patent and 7 published patent applications. Top assignee: Entrada Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiulong Shen. Retrieved from https://idiyas.com/inventor/xiulong-shen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xiulong Shen and Antisense Compound Delivery

Introduction

Xiulong Shen is an inventor based in Waltham, Massachusetts, whose patent work includes a composition designed to support the delivery of antisense compounds. He is associated with Entrada Therapeutics, Inc., a biotechnology company focused on developing therapeutics.

Latest Patents

Shen is named on one patent: “Compositions for Delivery of Antisense Compounds.” The patent concerns compositions intended to facilitate delivery of antisense compounds. His listed patent portfolio includes 1 patent.

Career Highlights

Shen’s recorded invention connects his work with research into delivery approaches for antisense compounds. His association with Entrada Therapeutics places this work within a biotechnology setting.

Collaborations

Shen’s listed coworkers include Mahboubeh Kheirabadi and Ziqing Qian. Their shared professional context reflects collaboration among researchers and colleagues in the biotechnology field.

Conclusion

Xiulong Shen’s patent on compositions for delivering antisense compounds represents his documented contribution to biotechnology innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…